John Reneau

John Reneau's work focuses on T-cell lymphomas, a group of blood cancers, with an emphasis on new drug therapies and understanding the biology that drives these cancers. His research spans early-phase clinical trials of novel targeted drugs (such as ITK inhibitors and antibody therapies) alongside laboratory studies of gene regulation and drug mechanisms in tumor cells. This work is aimed at improving treatment options for patients with relapsed or hard-to-treat T-cell lymphomas.

Publication output grew substantially from 2017 through a peak in 2023, followed by a decline in 2024-2025, though activity remains higher than in the early part of the decade.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026